Damora Therapeutics Inc (DMRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Operating Expenses | 8,583 | 11,159 | 13,492 | 13,525 | 13,622 |
| Operating Income | -8,583 | -11,159 | -13,492 | -13,525 | -13,622 |
| Other Income | 447 | 415 | 498 | -544 | -108 |
| Pre-tax Income | -8,136 | -10,744 | -12,994 | -14,069 | -13,730 |
| Net Income Continuous | -8,136 | -10,744 | -12,994 | -14,069 | -13,730 |
| Net Income | $-8,136 | $-10,744 | $-12,994 | $-14,069 | $-13,730 |
| EPS Basic Total Ops | -7.50 | -10.25 | -12.75 | -13.75 | -13.50 |
| EPS Basic Continuous Ops | -7.51 | -10.18 | -12.65 | -13.70 | -13.47 |
| EPS Diluted Total Ops | -7.50 | -10.25 | -12.75 | -13.75 | -13.50 |
| EPS Diluted Continuous Ops | -7.51 | -10.18 | -12.65 | -13.70 | -13.47 |
| EBITDA(a) | $-8,530 | $-11,236 | $-13,628 | $-13,385 | $-13,607 |